These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Inhalation treatment with glutathione in patients with cystic fibrosis. A randomized clinical trial. Griese M; Kappler M; Eismann C; Ballmann M; Junge S; Rietschel E; van Koningsbruggen-Rietschel S; Staab D; Rolinck-Werninghaus C; Mellies U; Köhnlein T; Wagner T; König S; Teschler H; Heuer HE; Kopp M; Heyder S; Hammermann J; Küster P; Honer M; Mansmann U; Beck-Speier I; Hartl D; Fuchs C; ; Hector A Am J Respir Crit Care Med; 2013 Jul; 188(1):83-9. PubMed ID: 23631796 [TBL] [Abstract][Full Text] [Related]
4. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Bishop C; Hudson VM; Hilton SC; Wilde C Chest; 2005 Jan; 127(1):308-17. PubMed ID: 15653998 [TBL] [Abstract][Full Text] [Related]
5. Increasing sputum levels of gamma-glutamyltransferase may identify cystic fibrosis patients who do not benefit from inhaled glutathione. Corti A; Griese M; Hector A; Pompella A J Cyst Fibros; 2017 May; 16(3):342-345. PubMed ID: 27988297 [TBL] [Abstract][Full Text] [Related]
7. Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Accurso FJ; Moss RB; Wilmott RW; Anbar RD; Schaberg AE; Durham TA; Ramsey BW; Am J Respir Crit Care Med; 2011 Mar; 183(5):627-34. PubMed ID: 21169471 [TBL] [Abstract][Full Text] [Related]
8. The effect of short-term, high-dose oral N-acetylcysteine treatment on oxidative stress markers in cystic fibrosis patients with chronic P. aeruginosa infection -- a pilot study. Skov M; Pressler T; Lykkesfeldt J; Poulsen HE; Jensen PØ; Johansen HK; Qvist T; Kræmer D; Høiby N; Ciofu O J Cyst Fibros; 2015 Mar; 14(2):211-8. PubMed ID: 25458464 [TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial. Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446 [TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Deterding R; Retsch-Bogart G; Milgram L; Gibson R; Daines C; Zeitlin PL; Milla C; Marshall B; Lavange L; Engels J; Mathews D; Gorden J; Schaberg A; Williams J; Ramsey B; Pediatr Pulmonol; 2005 Apr; 39(4):339-48. PubMed ID: 15704203 [TBL] [Abstract][Full Text] [Related]
11. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Balfour-Lynn IM; Lees B; Hall P; Phillips G; Khan M; Flather M; Elborn JS; Am J Respir Crit Care Med; 2006 Jun; 173(12):1356-62. PubMed ID: 16556691 [TBL] [Abstract][Full Text] [Related]
12. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641 [TBL] [Abstract][Full Text] [Related]
13. Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial. De Boeck K; Haarman E; Hull J; Lands LC; Moeller A; Munck A; Riethmüller J; Tiddens H; Volpi S; Leadbetter J; Charlton B; Malfroot A; J Cyst Fibros; 2017 May; 16(3):380-387. PubMed ID: 28258928 [TBL] [Abstract][Full Text] [Related]
14. Hyaluronic acid improves the tolerability of hypertonic saline in the chronic treatment of cystic fibrosis patients: a multicenter, randomized, controlled clinical trial. Ros M; Casciaro R; Lucca F; Troiani P; Salonini E; Favilli F; Quattrucci S; Sher D; Assael BM J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):133-7. PubMed ID: 23745525 [TBL] [Abstract][Full Text] [Related]
15. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Aitken ML; Bellon G; De Boeck K; Flume PA; Fox HG; Geller DE; Haarman EG; Hebestreit HU; Lapey A; Schou IM; Zuckerman JB; Charlton B; Am J Respir Crit Care Med; 2012 Mar; 185(6):645-52. PubMed ID: 22198974 [TBL] [Abstract][Full Text] [Related]
16. Improvement in clinical markers in CF patients using a reduced glutathione regimen: an uncontrolled, observational study. Visca A; Bishop CT; Hilton SC; Hudson VM J Cyst Fibros; 2008 Sep; 7(5):433-6. PubMed ID: 18499536 [TBL] [Abstract][Full Text] [Related]
17. [The effect of ipratropium bromide on lung function in patients with cystic fibrosis]. Wiebicke W; Poynter A; Montgomery M; Pagtakhan R Pneumologie; 1990 Feb; 44 Suppl 1():277-8. PubMed ID: 2142293 [TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Schnabel D; Grasemann C; Staab D; Wollmann H; Ratjen F; Pediatrics; 2007 Jun; 119(6):e1230-8. PubMed ID: 17545356 [TBL] [Abstract][Full Text] [Related]
19. Improved glutathione status in young adult patients with cystic fibrosis supplemented with whey protein. Grey V; Mohammed SR; Smountas AA; Bahlool R; Lands LC J Cyst Fibros; 2003 Dec; 2(4):195-8. PubMed ID: 15463873 [TBL] [Abstract][Full Text] [Related]
20. Inhaled mannitol improves lung function in cystic fibrosis. Jaques A; Daviskas E; Turton JA; McKay K; Cooper P; Stirling RG; Robertson CF; Bye PTP; LeSouëf PN; Shadbolt B; Anderson SD; Charlton B Chest; 2008 Jun; 133(6):1388-1396. PubMed ID: 18339790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]